

AtriCure, Inc.  
Form 10-Q  
November 07, 2008  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2008

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-51470

**AtriCure, Inc.**

Edgar Filing: AtriCure, Inc. - Form 10-Q

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of

**34-1940305**  
(I.R.S. Employer

incorporation or organization)

Identification No.)

**6033 Schumacher Park Drive**

**West Chester, OH 45069**

(Address of principal executive offices)

**(513) 755-4100**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated Filer  Accelerated Filer  Non-Accelerated Filer  Smaller reporting company   
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES  NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

**Class**  
Common Stock, \$.001 par value

**Outstanding at November 5, 2008**  
14,219,530

---

**Table of Contents**

**Table of Contents**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<b><u>Item 1. Financial Statements</u></b>	
<u>Condensed Consolidated Balance Sheets as of September 30, 2008 and December 31, 2007</u>	3
<u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2008 and 2007</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2008 and 2007</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	20
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	26
<u>Item 4. Controls and Procedures</u>	26
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1. Legal Proceedings</u>	27
<u>Item 1A. Risk Factors</u>	27
<u>Item 6. Exhibits</u>	29
<u>Signatures</u>	30
<u>Exhibit Index</u>	31

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****ATRICURE, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)**

	September 30, 2008	December 31, 2007
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 12,280,244	\$ 13,000,652
Short-term investments		7,006,041
Accounts receivable, less allowance for doubtful accounts of \$18,598 and \$26,181, respectively	8,716,091	7,189,512
Inventories, net	5,358,715	5,266,155
Other current assets	1,379,698	1,400,163
Total current assets	27,734,748	33,862,523
Property and equipment, net	4,239,144	4,466,060
Intangible assets	639,528	850,653
Goodwill	6,812,389	6,763,259
Restricted cash and cash equivalents	6,000,000	
Other assets	216,302	129,001
Total Assets	\$ 45,642,111	\$ 46,071,496
<b>Liabilities and Stockholders Equity</b>		
Current liabilities:		
Accounts payable	\$ 4,106,376	\$ 4,651,201
Accrued liabilities	4,128,748	3,762,455
Current maturities of debt and capital leases	33,383	825,146
Total current liabilities	8,268,507	9,238,802
Long-term debt and capital leases	6,045,342	282,475
Other liabilities	127,529	313,717
Total Liabilities	14,441,378	9,834,994
Commitments and contingencies (Note 9)		
Stockholders Equity:		
Common stock, \$.001 par value, 90,000,000 shares authorized and 14,219,429 and 14,132,424 issued and outstanding, respectively	14,219	14,132
Additional paid-in capital	105,642,541	103,524,814
Accumulated other comprehensive (loss)/income	(180,272)	5,286
Accumulated deficit	(74,275,755)	(67,307,730)
Total Stockholders Equity	31,200,733	36,236,502
Total Liabilities and Stockholders Equity	\$ 45,642,111	\$ 46,071,496

Edgar Filing: AtriCure, Inc. - Form 10-Q

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Revenues	\$ 14,802,001	\$ 12,054,459	\$ 43,190,660	\$ 35,157,448
Cost of revenues	3,396,038	2,760,418	10,121,826	7,518,066
Gross profit	11,405,963	9,294,041	33,068,834	27,639,382
Operating expenses:				
Research and development expenses	3,008,619	2,397,837	8,035,466	8,455,098
Selling, general and administrative expenses	10,215,477	9,805,004	32,573,233	30,125,026
Total operating expenses	13,224,096	12,202,841	40,608,699	38,580,124
Loss from operations	(1,818,133)	(2,908,800)	(7,539,865)	(10,940,742)
Other income (expense):				
Interest expense	(173,952)	(49,466)	(256,465)	(142,410)
Interest income	80,036	285,965	313,807	704,551
Other	142,071	74,125	514,498	690,916
Net loss	\$ (1,769,978)	\$ (2,598,176)	\$ (6,968,025)	\$ (9,687,685)
Basic and diluted loss per share	\$ (0.12)	\$ (0.18)	\$ (0.49)	\$ (0.74)
Weighted average shares outstanding Basic and diluted	14,208,232	14,125,230	14,181,155	13,129,204

See accompanying notes to condensed consolidated financial statements.

**Table of Contents****ATRICURE, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

	<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (6,968,025)	\$ (9,687,685)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation and amortization	2,165,464	1,662,198
Loss on disposal of equipment		6,852
Benefit from losses in accounts receivable	(2,858)	(40,297)
Share-based compensation expense	1,781,283	1,376,809
<b>Changes in assets and liabilities, excluding effects of acquired business:</b>		
Accounts receivable	(1,557,358)	(759,473)
Inventories	(154,548)	(337,010)
Other current assets	16,827	(105,677)
Accounts payable	(395,295)	136,989
Accrued liabilities	459,393	(297,261)
Other non-current assets and non-current liabilities	(230,423)	255,249
<b>Net cash used in operating activities</b>	<b>(4,885,540)</b>	<b>(7,789,306)</b>
<b>Cash flows from investing activities:</b>		
Purchases of property & equipment	(1,584,279)	(2,268,489)
Purchases of available-for-sale securities	(1,900,756)	(3,987,447)
Maturities of available-for-sale securities	8,894,670	4,608,000
Change in restricted cash and cash equivalents	(6,000,000)	
Cash paid for acquisition	(417,292)	(3,337,103)
<b>Net cash used in investing activities</b>	<b>(1,007,657)</b>	<b>(4,985,039)</b>
<b>Cash flows from financing activities:</b>		
Payments on debt and capital leases	(713,801)	(292,792)
Proceeds from borrowings of debt	6,000,000	
Payment of debt fees and premium on retirement of debt	(269,107)	
Proceeds from stock option exercises	239,065	169,873
Net proceeds from sale of stock		15,317,002
<b>Net cash provided by financing activities</b>	<b>5,256,157</b>	<b>15,194,083</b>
Effect of exchange rate changes on cash	(83,368)	(79,882)
Net (decrease) increase in cash and cash equivalents	(720,408)	2,339,856
Cash and cash equivalents beginning of period	13,000,652	14,890,383
<b>Cash and cash equivalents end of period</b>	<b>\$ 12,280,244</b>	<b>\$ 17,230,239</b>
<b>Supplemental cash flow information:</b>		
Cash paid for interest	\$ 59,275	\$ 57,757
<b>Non-cash investing and financing activities:</b>		
Purchases of property and equipment in current liabilities	\$ 49,473	\$ 123,210
Assets acquired through capital lease	102,197	

Edgar Filing: AtriCure, Inc. - Form 10-Q

See accompanying notes to condensed consolidated financial statements.



---

**Table of Contents**

**ATRICURE, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Nature of the Business** AtriCure, Inc. (the Company) was incorporated in the State of Delaware on October 31, 2000 to focus on the surgical treatment of atrial fibrillation ( AF ). AF is a rapid, irregular quivering of the upper chambers of the heart. The Company sells its medical devices to hospitals and medical centers in the United States and internationally.

**Basis of Presentation** The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ( SEC ). The accompanying interim financial statements are unaudited, but in the opinion of management, contain all the normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with generally accepted accounting principles applicable to interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ( GAAP ) have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period.

The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company included in the Company's annual report on Form 10-K, as amended, for the year ended December 31, 2007 filed with the SEC.

**Principles of Consolidation** The consolidated financial statements include the accounts of the Company and AtriCure Europe B.V., the Company's wholly owned subsidiary incorporated in the Netherlands. Intercompany accounts and transactions have been eliminated in consolidation.

**Cash and Cash Equivalents** The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying condensed consolidated financial statements.

**Revenue Recognition** Revenues are generated primarily from the sale of the Company's disposable surgical devices. Pursuant to the Company's standard terms of sale, revenues are recognized when title to the goods and risk of loss transfers to customers and there are no remaining obligations that will affect the customers' final acceptance of the sale. Generally, the Company's standard terms of sale define the transfer of title and risk of loss to occur upon shipment to the respective customer. The Company generally does not maintain any post-shipping obligations to the recipients of the products. Product revenues include shipping and handling revenues of \$195,207 and \$109,639 for the three months ended September 30, 2008 and 2007, respectively, and \$600,042 and \$282,583 for the nine months ended September 30, 2008 and 2007, respectively. Cost of freight for shipments made to customers is included in cost of revenues. Sales taxes collected from customers and remitted to governmental authorities are excluded from product revenues. The Company sells its products primarily through a direct sales force and through AtriCure Europe B.V. Terms of sale are generally consistent for both end-users and distributors and payment terms are generally net 30 days.

The Company complies with the SEC Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements ( SAB 101 ), as amended by SAB 104. SAB 101 sets forth guidelines on the timing of revenue recognition based upon factors such as passage of title, installation, payment terms and ability to return products. The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured.

**Sales Returns and Allowances** The Company maintains a provision for sales returns and allowances as a result of defective or damaged products or when price reductions are given to customers. The provision is reviewed periodically and estimated based primarily on a specific identification basis. The Company expects to refine the methodology utilized to estimate this provision as it accumulates additional historical data and experience. Increases to the provision result in a reduction of revenues.

**Allowance for Uncollectible Accounts Receivable** The Company systematically evaluates the collectibility of accounts receivable and determines the appropriate reserve for doubtful accounts. In determining the amount of the reserve, the Company considers aging of account balances, historical credit losses, customer-specific information, and other relevant factors. Increases to the allowance for doubtful accounts result in a corresponding expense. Periodically, the Company reviews accounts receivable and adjusts the allowance based on current

Edgar Filing: AtriCure, Inc. - Form 10-Q

circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed.

**Table of Contents**

**Inventories** Inventories are stated at the lower of cost or market using the first-in, first-out ( FIFO ) cost method and consist of raw materials, work in process, and finished goods. Reserves are estimated for excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of its net realizable value. Write-offs are recorded when a product is destroyed. The Company reviews inventory on hand at least quarterly and records provisions for excess and obsolete inventory based on several factors including current assessment of future product demand, anticipated release of new products into the market, historical experience and product expiration. The Company's industry is characterized by rapid product development and frequent new product introductions. Uncertain timing of product approvals, variability in product launch strategies, product recalls and variation in product utilization all impact the estimates related to excess and obsolete inventory. Inventories consisted of the following:

	September 30, 2008	December 31, 2007
Raw material	\$ 2,802,080	\$ 1,943,041
Work in process	1,243,011	891,798
Finished goods	1,500,566	2,548,174
Reserve for obsolescence	(186,942)	(116,858)
<b>Inventories, net</b>	<b>\$ 5,358,715</b>	<b>\$ 5,266,155</b>

**Property and Equipment** Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line method for financial reporting purposes over the estimated useful lives of the assets. The estimated useful life by major asset category is the following: machinery and equipment is three to seven years, computer and other office equipment is three years, furniture and fixtures is three to seven years, and leasehold improvements are the shorter of their useful life or remaining lease term. Maintenance and repair costs are expensed as incurred.

Included in property and equipment are generators and other capital equipment (such as the Company's ASB, or switch box) that are loaned at no cost to direct customers who use the Company's disposable products. These generators are depreciated over three years and such depreciation is included in cost of revenues. The total of such depreciation was \$264,954 and \$197,810 for the three months ended September 30, 2008 and 2007, respectively and \$862,564 and \$533,375 for the nine months ended September 30, 2008 and 2007, respectively.

**Impairment of Long-Lived Assets (Other than Goodwill)** The Company reviews property and equipment and definite-lived intangibles for impairment using its best estimates based on reasonable and supportable assumptions and projections in accordance with Statement of Financial Accounting Standards ( SFAS ) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. The Company did not recognize any impairment of long-lived assets for the three and nine months ended September 30, 2008 and 2007, respectively.

**Goodwill and Intangible Assets** As of September 30, 2008, the Company had \$6,812,389 in goodwill, which represents the excess of costs over the fair value of the net assets acquired in business combinations. The Company tests its goodwill for impairment annually during the fourth quarter, or more frequently if impairment indicators are present, to determine if the fair value of the business can support the amount of goodwill. The goodwill tests include discounted cash flow models and a market valuation approach. The discounted cash flow models include assumptions about future market conditions and operating results. If an impairment test indicates the fair value cannot support the amount of goodwill recorded, the Company will be required to record a goodwill impairment charge. As a result, the value of the assets could be significantly reduced, which would increase operating expenses and reduce net income for the period in which the charge occurs. As of September 30, 2008 and 2007, there was no indication that an impairment existed, and the Company did not recognize any impairment during the three or nine months ended September 30, 2008 and 2007, respectively.

Intangible assets with determinable useful lives are amortized on a straight-line basis over the estimated periods benefited.

**Restricted Cash and Cash Equivalents** The first \$6,000,000 of availability under the Company's revolving credit facility is available in \$2,000,000 increments, tied to a corresponding balance deposited in a restricted securities account. The Company will be allowed, provided there are no events of default, to decrease and increase the account value in the restricted securities account in its sole discretion, thereby correspondingly decreasing or increasing the revolving credit availability between \$2,000,000 and \$6,000,000 in \$2,000,000 increments. As of September 30, 2008 \$6,000,000 had been borrowed under the revolving credit facility. Revolving credit availability between \$6,000,000 and \$10,000,000 also requires a cash equivalent to borrowing ratio of not less than 1.25 to 1.0.



**Table of Contents**

**Grant Income** The Company receives research grants, which are recognized as funds are expended and not as awarded by awarding agencies.

**Income Taxes** Income taxes have been computed using the asset and liability method, under which deferred income taxes are provided for the temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities. Deferred taxes are measured using provisions of currently enacted tax laws. A valuation allowance against deferred tax assets is recorded when it is more likely than not that such assets will not be fully realized. Tax credits are accounted for as a reduction of income taxes in the year in which the credit originates.

The Company's estimate for the valuation allowance for deferred tax assets requires it to make significant estimates and judgments about its future operating results. The Company's ability to realize the deferred tax assets depends on its future taxable income, as well as limitations on their utilization. A deferred tax asset is reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized prior to its expiration. The projections of the Company's operating results on which the establishment of a valuation allowance is based involve significant estimates regarding future demand for the Company's products, competitive conditions, product development efforts, approvals of regulatory agencies, and product cost. If actual results differ from these projections, or if the Company's expectations of future results change, it may be necessary to adjust the valuation allowance.

**Net Loss Per Share** Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, net loss per share excludes the effect of options outstanding, which as of September 30, 2008 and 2007 were 2,607,773 and 2,271,747 respectively, as options outstanding were anti-dilutive. The number of shares calculated for basic net loss per share is also used for the diluted net loss per share calculation.

**Accumulated Other Comprehensive Income** Other comprehensive income consisted of the following:

	Unrealized Gains (Losses) on Investments	Foreign Currency Translation Adjustment	Other Comprehensive Income
Balance as of December 31, 2007	\$ 12,129	\$ (6,843)	\$ 5,286
January 1, 2008 to September 30, 2008 change	(12,129)	(173,429)	(185,558)
Balance as of September 30, 2008	\$	\$ (180,272)	\$ (180,272)

**Foreign Currency Transaction Gain** The Company recorded foreign currency transaction gains (losses) of \$19,261 and \$(64) for the three months ended September 30, 2008 and 2007, respectively and \$76,884 and \$204,393 for the nine months ended September 30, 2008 and 2007 respectively, in connection with partial settlements of its intercompany receivable balance with its subsidiary.

**Research and Development** Research and development costs are expensed as incurred. These costs include compensation and other internal and external costs associated with the development and research related to new products or concepts, preclinical studies, clinical trials, and the cost of products used in trials and tests.

## **Table of Contents**

**Share-Based Employee Compensation** On January 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment, ( SFAS 123(R) ), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options and employee stock purchases related to an employee stock purchase plan, based on estimated fair values. SFAS 123(R) supersedes the Company's previous accounting under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees ( APB 25 ) for periods beginning in 2006. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 ( SAB 107 ) relating to SFAS 123(R). The Company has applied the provisions of SAB 107 in its adoption of SFAS 123(R). The Company adopted SFAS 123(R) using the modified prospective transition method. Share-based compensation expense recognized under SFAS 123(R) for the three months ended September 30, 2008 and 2007 was \$571,304 and \$456,947, respectively and \$1,692,910 and \$999,216 for the nine months ended September 30, 2008 and 2007, respectively, on a before and after tax basis, which consisted of share-based compensation expense related to employee stock options.

SFAS 123(R) requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's Condensed Consolidated Statements of Operations. The expense has been reduced for estimated forfeitures. SFAS 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

The Company estimates the fair value of options on the date of grant using the Black-Scholes option-pricing model ( Black-Scholes model ). The Company's determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company's stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include but are not limited to the Company's expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors.

On November 10, 2005, the Financial Accounting Standards Board ( FASB ) issued FASB Staff Position No. FAS 123(R)-3 Transition Election Related to Accounting for Tax Effects of Share-Based Payment Awards (the FASB Staff Position ). The Company has elected to adopt the alternative transition method provided in the FASB Staff Position for calculating the tax effects of share-based compensation pursuant to SFAS 123(R). The alternative transition method includes simplified methods to establish the beginning balance of the additional paid-in capital pool ( APIC pool ) related to the tax effects of employee share-based compensation and to determine the subsequent impact on the APIC pool and Consolidated Statements of Cash Flows of the tax effects of employee share-based compensation awards that are outstanding upon adoption of SFAS 123(R).

**Use of Estimates** The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Accounting for Business Combinations** In accounting for business combinations, the Company applies the accounting requirements of Statement of Financial Accounting Standards No. 141, Business Combinations ( SFAS 141 ), which requires the recording of net assets of acquired businesses at fair value. In developing estimates of the fair value of acquired assets and assumed liabilities, the Company analyzes a variety of factors including market data, estimated future cash flows of the acquired operations, industry growth rates, current replacement costs, and market rate assumptions for contractual obligations. This valuation requires significant estimates and assumptions, especially with respect to the valuation of intangible assets.

**Fair Value Disclosures** The carrying amounts of the Company's financial instruments, including cash and cash equivalents, accounts receivable, restricted cash and cash equivalents, other assets, accounts payable, accrued expenses, other liabilities and variable interest rate debt, approximate their fair values.

## **2. RECENT ACCOUNTING PRONOUNCEMENTS**

In December 2007, the FASB issued SFAS No. 141(R), which replaces FAS 141. SFAS 141(R) establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. FAS 141(R) is to be applied prospectively to business combinations for which the acquisition date is on or after an entity's fiscal year that begins after December 15, 2008, except for certain tax adjustments for prior business combinations. The Company is currently evaluating the effect, if any, that the adoption of SFAS No. 141(R) will have on its financial statements.



**Table of Contents**

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements – an amendment of ARB No. 51 ( SFAS 160 ). SFAS 160 establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Specifically, this statement requires the recognition of a noncontrolling interest (minority interest) as equity in the consolidated financial statements and separate from the parent’s equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. SFAS 160 clarifies that changes in a parent’s ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss will be measured using the fair value of the noncontrolling equity investment on the deconsolidation date. SFAS 160 also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Earlier adoption is prohibited. The Company does not believe the adoption of SFAS 160 will have any impact on its consolidated financial statements as the Company has a 100% controlling interest in its subsidiary.

In March 2008, the FASB issued SFAS No. 161 – Disclosures about Derivative Instruments and Hedging Activities – an amendment of SFAS 133 ( SFAS No. 161 ). SFAS No. 161 is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, financial performance, and cash flows. This statement will be applicable to the Company on January 1, 2009. The Company is currently evaluating the impact that this standard will have on its financial statements and will provide the required disclosure upon adoption, if any.

In April 2008, the FASB issued FSP No. FAS 142-3, – Determination of the Useful Life of Intangible Assets – ( FSP No. FAS 142-3 ). FSP No. FAS 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, – Goodwill and Other Intangible Assets. The intent of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS No. 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS No. 141(R) and other GAAP. FSP No. FAS 142-3 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2008. The Company does not expect the adoption of FSP No. FAS 142-3 to have a material impact on its financial statements.

In May 2008, the FASB issued SFAS No. 162, – The Hierarchy of Generally Accepted Accounting Principles – ( SFAS No. 162 ). SFAS No. 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements of nongovernmental entities that are presented in conformity with GAAP in the United States. SFAS No. 162 is effective 60 days following approval by the Securities and Exchange Commission ( SEC ) of the Public Company Accounting Oversight Board amendments to AU Section 411, – The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles . The Company does not expect the adoption of SFAS No. 162 to have a material impact on its financial statements.

Effective January 1, 2008, the Company adopted EITF 07-3, – Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities – ( EITF 07-3 ). EITF 07-3 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. The adoption did not have a material impact on the Company’s consolidated results of operations or financial condition.

Effective January 1, 2008, the Company adopted SFAS No. 157, – Fair Value Measurements – ( SFAS 157 ). In February 2008, the FASB issued FASB Staff Position No. FAS 157-2, – Effective Date of FASB Statement No. 157 , which provides a one year deferral of the effective date of SFAS 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. Therefore, the Company has adopted the provisions of SFAS 157 with respect to its financial assets and liabilities only. SFAS 157 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under SFAS 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under SFAS 157 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 Quoted prices in active markets for identical assets or liabilities.



## Edgar Filing: AtriCure, Inc. - Form 10-Q

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

**Table of Contents**

Effective January 1, 2008, the Company adopted SFAS No. 159 The Fair Value Option for Financial Assets and Financial Liabilities ( SFAS 159 ). SFAS 159 allows an entity the irrevocable option to elect fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to adopt the fair value option under this Statement.

**3. FAIR VALUE**

In accordance with SFAS 157, the following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments) and liabilities measured at fair value on a recurring basis as of September 30, 2008:

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)	(Total)
<b>Assets:</b>				
Money market funds		\$ 17,638,996		\$ 17,638,996
U.S. Government Securities				
Medium-term notes				
<b>Total assets</b>	<b>\$</b>	<b>\$ 17,638,996</b>	<b>\$</b>	<b>\$ 17,638,996</b>
<b>Liabilities:</b>				
Derivative instruments			\$ 348,307	\$ 348,307
<b>Total liabilities</b>	<b>\$</b>	<b>\$</b>	<b>\$ 348,307</b>	<b>\$ 348,307</b>

Certain of the Company's share-based payment arrangements are outside the scope of SFAS 123(R) and are subject to Emerging Issues Task Force ( EITF ) Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, which requires vested stock options held by certain non-employee consultants to be accounted for as liability awards until these awards are exercised or forfeited. The fair value of these awards is remeasured at each financial statement date until the awards are settled or expire. In calculating the fair value of the options they are estimated on the grant date using the Black-Scholes model subject to change in stock price utilizing assumptions of risk-free interest rate, contractual life of option, expected volatility, weighted average volatility and dividend yield. Due to the lack of certain observable market quotes the Company utilizes valuation models that rely on some Level 3 inputs. Specifically, due to the Company's limited trading history, the Company used an equal weighting of both the Company's implied volatility and the implied volatility of a group of comparable companies in determining the Company's volatility.

	Fair Value Measurements Using Significant Other Unobservable Inputs (Level 3) Derivative Instruments
<b>Beginning Balance</b>	<b>\$ 660,827</b>
Total gains (realized/unrealized)	
Included in earnings	215,054
Included in other comprehensive income	
Purchases, issuances and settlements	97,466
Transfer in and/or out of Level 3	
<b>Ending Balance</b>	<b>\$ 348,307</b>
	\$ 215,054

## Edgar Filing: AtriCure, Inc. - Form 10-Q

The amount of total gains for the period included in earnings (or changes in net assets) attributable to the change in unrealized gains or losses relating to assets still held at reporting date

**Table of Contents****4. INVESTMENTS**

Investments consisted of the following:

	Cost Basis	Unrealized Gain (Loss)	Fair Value
<b>December 31, 2007</b>			
U.S. Government Securities	\$ 1,497,662	\$ 3,283	\$ 1,500,945
Medium-term notes	1,494,852	568	1,495,420
Corporate notes	1,800,936	902	1,801,838
Commercial paper	797,635	45	797,680
Corporate bonds	1,402,827	7,331	1,410,158
	<b>\$ 6,993,912</b>	<b>\$ 12,129</b>	<b>\$ 7,006,041</b>

The Company has not experienced any significant realized gains or losses on its investments in the periods presented in the Condensed Consolidated Statements of Operations. No investments were outstanding at September 30, 2008.

**5. BUSINESS COMBINATION**

On August 7, 2007, the Company acquired the Frigitronics® CCS-200 product line for use in cardiovascular cryosurgery, which includes a console and a variety of reusable probes, from CooperSurgical, Inc. ( Cooper ), for an aggregate purchase price of \$3,758,641. Of the purchase price, \$3,244,244 was paid in cash at closing, funded from cash on-hand, and \$417,292 was payable under an unsecured promissory note, which was paid in full in January 2008. The acquisition complemented the Company's open-heart product offering. The purchase price allocation resulted in goodwill of \$2,971,552, which is deductible for tax purposes. Intangible assets acquired were \$320,000, consisting of \$220,000 for use of a tradename and \$100,000 related to a non-compete arrangement. The Company also incurred legal and professional expenses associated with the acquisition of \$97,105.

The purchase price is as follows:

Cash paid	\$ 3,244,244
Portion of unsecured promissory note allocated to purchase price paid in January 2008	417,292
Acquisition-related costs	97,105
 Total purchase price	 \$ 3,758,641

The following table summarizes the fair values of the assets acquired and liabilities assumed on August 7, 2007. The allocation of the excess purchase price was based upon estimates and assumptions.

Inventories	\$ 451,011
Property and equipment	17,578
Goodwill	2,971,552
Intangible assets	320,000
 Assets acquired	 3,760,141
Accrued liabilities	1,500
 Net assets acquired	 \$ 3,758,641



**Table of Contents**

On an unaudited pro forma basis, assuming the acquisition of the product line had occurred at January 1, 2007, the Company's consolidated results would not differ materially from the historical results as reported.

**6. INTANGIBLE ASSETS**

Intangible assets with definite lives are amortized over their estimated useful lives. The following table provides a summary of the Company's intangible assets with definite lives:

	<b>Proprietary manufacturing technology</b>	<b>Non-compete agreement</b>	<b>Tradename</b>	<b>Total</b>
Net carrying amount as of December 31, 2006	\$ 772,778	\$	\$	\$ 772,778
Gross carrying amount recorded		100,000	220,000	320,000
Amortization	(214,000)	(5,208)	(22,917)	(242,125)
Net carrying amount as of December 31, 2007	558,778	94,792	197,083	850,653
Amortization	(160,500)	(9,375)	(41,250)	(211,125)
Net carrying amount as of September 30, 2008	\$ 398,278	\$ 85,417	\$ 155,833	\$ 639,528

Amortizable intangible assets are being amortized over eight years for a non-compete arrangement, four years for tradename usage and five years for proprietary manufacturing technology. Amortization expense related to intangible assets with definite lives was \$70,375 and \$70,167 for the three months ended September 30, 2008 and 2007, respectively and \$211,125 and \$177,167 for the nine months ended September 30, 2008 and 2007, respectively.

Future amortization expense related to intangible assets is projected as follows:

<b>Year</b>	<b>Amortization</b>	
2008	\$ 70,375	October 1, 2008 to December 31, 2008
2009	281,500	
2010	198,278	
2011	44,583	
2012	12,500	
2013 and thereafter	32,292	
	\$ 639,528	

The changes in the net carrying amount of goodwill for the periods ended September 30, 2008 and 2007 are as follows:

Net carrying amount as of December 31, 2006	\$ 3,840,837
Goodwill amount recorded	2,922,422
Net carrying amount as of December 31, 2007	6,763,259
Adjustment to goodwill	49,130
Net carrying amount as of September 30, 2008	\$ 6,812,389



**Table of Contents****7. ACCRUED LIABILITIES**

Accrued liabilities consisted of the following:

	September 30, 2008	December 31, 2007
Accrued commissions	\$ 1,421,406	\$ 1,157,124
Accrued bonus	832,748	589,673
Liability for vested non-employee options	348,307	660,827
Accrued vacation	327,526	327,526
Other accrued liabilities	1,198,761	1,027,305
	\$ 4,128,748	\$ 3,762,455

**8. INDEBTEDNESS**

On July 1, 2008, the Company entered into a two-year credit facility with National City Bank. The credit facility matures on July 1, 2010 and is secured by all of the Company's assets and property, tangible and intangible.

The credit facility provides for a revolving credit facility of up to \$10,000,000 and a letter of credit facility for an amount equal to the lesser of: (i) \$1,500,000 or (ii) the availability under the revolving credit facility. The Company must maintain all of its primary deposit accounts with National City or a subsidiary of National City, and was required to deliver cash and/or money market funds having an aggregate value of at least \$2,000,000 to be held in a restricted securities account. This balance will remain in the restricted account until all of the Company's obligations under the credit facility are paid in full.

The first \$6,000,000 of availability under the revolving credit facility is available in \$2,000,000 increments, tied to a corresponding balance deposited in the restricted securities account. The Company will be allowed, provided there are no events of default, to decrease and increase the account value in the restricted securities account in its sole discretion, thereby correspondingly decreasing or increasing the revolving credit availability between \$2,000,000 and \$6,000,000 in \$2,000,000 increments. Revolving credit availability between \$6,000,000 and \$10,000,000 also requires a cash equivalent to borrowing ratio of not less than 1.25 to 1.0. The revolving credit availability is also subject at all times to adequate levels of eligible accounts receivables and inventory, among other factors.

Interest under the credit facility accrues at one month LIBOR (London Interbank Offered Rate) plus 2.25% per annum or if one month LIBOR is unavailable, as provided under the credit agreement, then the interest rate shall be a fluctuating rate equal to the prime rate publicly announced from time to time by National City. For letters of credit, the Company will pay a fee at a rate per annum equal to 1.50% on the amount available to be drawn under the letter of credit from the issuance date (and, as applicable, each renewal date) up to the expiration date. During certain events of default described in the credit agreement, the applicable interest rate increases by 2%.

The credit facility contains customary negative covenants, including limitations on liens, investments and the incurrence of additional indebtedness, and customary affirmative covenants, including reporting with respect to financial statements, receivables, inventory, material contracts, and FDA inspections. In addition, the credit facility contains a financial covenant that requires the Company's loss before considering interest, taxes, depreciation and amortization to be no more than \$15,000,000 per annum. The credit facility also contains customary events of default, including cross-defaults on the Company's indebtedness in excess of \$250,000.

As of September 30, 2008, \$6,000,000 was outstanding under the credit facility.

On July 2, 2008, as a condition to entering into the credit facility, the Company paid off in full its outstanding indebtedness to Lighthouse Capital Partners V, L.P. The Company paid \$713,032 to Lighthouse, which consisted of outstanding principal, accrued interest and a final payment fee due at maturity equal to 15% of borrowings under the facility with Lighthouse.

**9. COMMITMENTS AND CONTINGENCIES***Operating Leases*



## Edgar Filing: AtriCure, Inc. - Form 10-Q

The Company leases various types of office, manufacturing and warehouse facilities and equipment under noncancelable operating leases that expire at various terms through 2011.

---

## **Table of Contents**

### ***Royalty Agreement***

On November 21, 2005, the Company entered into a Royalty Agreement, effective as of October 1, 2005, with Randall K. Wolf, M.D., the co-inventor of the Lumitip dissector. Pursuant to the terms of the agreement, the Company will pay to Dr. Wolf royalties based on revenues from sales of the Lumitip dissector and certain other inventions, improvements or ideas, at royalty rates which range from 1.5% to 15% of such revenues. During the term of the agreement the Company is required to pay Dr. Wolf a minimum of \$50,000 in royalties per quarter and up to an aggregate of \$2,000,000 in royalties during the term of the agreement. The agreement terminates on December 31, 2009; however, the Company and Dr. Wolf each have the right at any time to terminate the agreement immediately for cause. Royalties earned by Dr. Wolf related to sales of the Lumitip dissector were \$50,000 and \$50,000 for the three months ended September 30, 2008 and 2007, respectively, and \$150,000 and \$150,000 for the nine months ended September 30, 2008 and 2007, respectively.

### ***Consultant Agreements***

The Company has entered into consulting agreements with several physicians. The agreements are typically for one year in length and define the scope of services to be provided by the physicians. The monthly compensation to the physicians ranges from \$2,000-\$5,000 per month.

### ***Purchase Agreement***

On June 15, 2007, the Company entered into a purchase agreement with Micropace Pty Ltd Inc., ( Micropace ), which was amended in June 2008. Under the amended agreement, Micropace is to design, engineer, develop, produce, and provide, a derivative of one of their products tailored for the cardiac surgical environment, known as the ORLab for worldwide distribution by the Company. Pursuant to the terms of the agreement, the Company is required to purchase in year one (12 month period commencing on December 15, 2007) 70 units (estimated to total \$1,200,000), and in years two and three 80 units each year (estimated to total \$1,400,000 each year). In addition, the Company agreed to purchase a minimum of four ORLab product demonstration units in the first 12 months at an estimated cost of \$40,000.

### ***Grant Rights and Obligations***

On July 18, 2006, the Company entered into an Agreement effective as of June 6, 2005 with The Cleveland Clinic relating to the Company's rights and obligations with respect to the publicly announced grants from the State of Ohio for, among other things, the creation of an Atrial Fibrillation Innovation Center. Pursuant to the terms of the Agreement, the Company is required to supply personnel and materials to accomplish certain research-related activities in connection with the grant and, over a three and one-half year period, the Company will receive up to a total of approximately \$900,000 for personnel and materials and The Cleveland Clinic will acquire up to approximately \$2,400,000 in capital equipment for the Company's use in support of its performance of the Agreement. Over the period of the agreement, the Company is required to expend up to approximately \$7,700,000 for operating expenses and up to approximately \$4,800,000 for capital expenses in support of the Agreement. The Company believes these amounts represent ordinary course expenditures that it would have otherwise anticipated making.

The terms of the Agreement specify the division of ownership of intellectual property developed in the performance of the Agreement and provide, among other things, that the Company will own all intellectual property it develops alone and certain intellectual property that is jointly developed and it will have the option to license certain intellectual property that is owned by The Cleveland Clinic and developed in the performance of the Agreement. The Agreement was amended in June 2008 to modify the original termination date from December 6, 2008 to December 31, 2009. However, the Company and The Cleveland Clinic may terminate the Agreement at any time by giving 30 days prior written notice. The Company recorded \$74,187 and \$74,190 of grant income related to the grant for the three months ended September 30, 2008 and 2007 respectively and \$222,561 and \$486,523 for the nine months ended September 30, 2008 and 2007, respectively.

---

**Table of Contents*****Legal Proceedings******Class Action Lawsuit***

The Company and certain of its current and former officers were named as defendants in a purported securities class action lawsuit filed in the United States District Court for the Southern District of New York (*Levine v. AtriCure, Inc.*, Case No. 06 CV 14324 (United States District Court for the Southern District of New York)). The suit alleges violations of the federal securities laws and seeks damages on behalf of purchasers of the Company's common stock during the period from the Company's initial public offering in August 2005 through February 16, 2006. The Company believes that the allegations are without merit and intends to vigorously defend against them. The Company filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction. This motion was denied in September 2007, and a motion for reconsideration of that denial is pending.

***Department of Justice Investigation***

The Company received a letter on October 27, 2008 from the U.S. Department of Justice-Civil Division (the DOJ) informing the Company that the DOJ was conducting an investigation for potential False Claims Act and common law violations relating to the Company's surgical ablation devices. Specifically, the letter states that the DOJ is investigating the Company's marketing practices utilized in connection with its surgical ablation system to treat atrial fibrillation, a specific use outside the Federal Food and Drug Administration's 510(k) clearance. The letter also states that the DOJ is investigating whether AtriCure instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes. On November 3, 2008, the Company received a letter from the DOJ outlining a document request. The Company is in the process of reviewing and compiling the requested information.

The Company may from time to time become a party to additional legal proceedings.

**10. INCOME TAX PROVISION**

In July 2006, FASB issued Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* an Interpretation of FASB Statement No. 109 (FIN 48), which became effective for the Company beginning on January 1, 2007. FIN 48 addresses the determination of how tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN 48, the Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. On January 1, 2007, the Company adopted the provisions of FIN 48. The Company examined the tax positions and concluded that each meets the more-likely-than-not recognition threshold of FIN 48 and is appropriately measured. Application of the provisions of FIN 48 therefore did not result in any change to the Company's tax account balances and the Company does not expect any significant unrecognized tax benefits to arise over the next twelve months.

The Company currently has not had to accrue interest and penalties related to unrecognized tax benefits, however when or if the situation occurs the Company will recognize interest and penalties within the income tax expense line in the accompanying Condensed Consolidated Statements of Operations and within the related tax liability line in the Condensed Consolidated Balance Sheets.

The Company files federal, state, and foreign income tax returns in jurisdictions with varying statutes of limitations. Generally, all of the Company's federal, state and foreign tax filings remain subject to examination by the relevant tax authority until full utilization of net operating loss carryforwards.

**11. EQUITY COMPENSATION PLANS**

As of September 30, 2008, the Company had two equity compensation plans: the 2001 Stock Option Plan and the 2005 Equity Incentive Plan. The 2001 plan is no longer used to grant options.

Under the 2005 Plan, the Board of Directors may grant incentive stock options to employees and any parent or subsidiary's employees, and may grant nonstatutory stock options, stock purchase rights, restricted stock, stock appreciation rights, performance units or performance shares to employees, directors and consultants of the Company and any parent or subsidiary's employees, directors and consultants. The administrator (which is made up of the Company's Board of Directors or a committee of the board) has the power to determine the terms of any awards, including the exercise price of options, the number of shares subject to each award, the exercisability of the awards and the form of consideration.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

Options granted under the 2001 and 2005 Plans generally expire 10 years from the date of grant. Options granted from the 2001 plan are generally exercisable beginning one year from the date of grant in cumulative yearly amounts of 25% of the shares granted. Options granted from the 2005 plan generally vest over a four year period at a rate of 25% on the first anniversary date of the grant and ratably each month thereafter.

**Table of Contents**

As of September 30, 2008, 4,340,215 shares were authorized for issuance under the 2005 Plan. The shares authorized for issuance under the 2005 plan include (a) shares authorized but unissued under the 2001 Plan as of August 10, 2005, (b) shares returned to the 2001 Plan as the result of termination of options or the repurchase of shares issued under such plan, and (c) annual increases in the number of shares available for issuance on the first day of each year equal to the lesser of:

3.25% of the outstanding shares of common stock on the first day of the fiscal year;

825,000 shares; or

an amount the Company's Board of Directors may determine.

On January 1, 2008, an additional 459,304 shares were authorized for issuance under the 2005 Plan representing 3.25% of the outstanding shares on this date.

Activity under the Plans was as follows:

	Number of Shares Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2008	2,296,035	\$ 8.11		
Granted	579,000	\$ 10.59		
Forfeited	(180,257)	\$ 10.21		
Exercised	(87,005)	\$ 2.75		
Outstanding at September 30, 2008	2,607,773	\$ 8.64	7.45	\$ 5,641,390
Expected to Vest	2,460,832	\$ 8.53	7.34	\$ 5,619,134
Exercisable at September 30, 2008	1,292,586	\$ 6.80	6.07	\$ 5,208,318

As of September 30, 2008, there were 1,234,960 shares available for future grants under the Plans.

The total intrinsic value of options exercised during the three months ended September 30, 2008 and 2007 was \$182,386 and \$65,000, respectively and approximately \$769,153 and \$1,273,000 for the nine months ended September 30, 2008 and 2007, respectively. Due to the Company's current tax position, no tax benefit was recognized as a result of option exercises for the three and nine month period ended September 30, 2008 and 2007. Additionally, there was no impact on operating or financing activities in the Company's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2008 and 2007 as a result of the exercise of stock options, other than the recognition of \$239,065 and \$169,873, respectively, in cash receipts as a result of stock option exercises.

The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant. The Company issues shares of common stock to satisfy stock option exercises.

**Table of Contents****Valuation and Expense Information under FAS 123(R)**

The following table summarizes share-based compensation expense related to employee stock options under SFAS 123(R), which was allocated as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Cost of revenues	\$ 36,849	\$ 21,864	\$ 95,216	\$ 59,037
Research and development expenses	75,610	71,724	209,263	162,745
Selling, general and administrative expenses	458,845	363,359	1,388,431	777,434
Total stock-based compensation	\$ 571,304	\$ 456,947	\$ 1,692,910	\$ 999,216

In calculating compensation expense under SFAS 123 and SFAS 123(R), the fair value of the options is estimated on the grant date using the Black-Scholes model including the following assumptions:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Risk free interest rate	3.54%	4.27%	2.88% to 3.54%	4.27% to 5.07%
Expected life of option (years)	6.25	6.0	6.0 to 6.5	6.0
Expected volatility of stock	43.00%	44.00%	43.00% to 43.50%	44.00% to 45.00%
Weighted-average volatility	43.00%	44.00%	43.34%	44.24%
Dividend yield	0.00%	0.00%	0.00%	0.00%

The risk-free interest rate assumption is based upon the U.S. treasury yield curve at the time of grant for the expected option life.

Due to the company's limited operating and trading history, volatility is estimated for both the three-month period and the nine-month period ended September 30, 2008 based on an equal weighting of both the Company's trading history and other companies in the industry. Due to the Company's limited operating and trading history, for options granted prior to 2008, volatility was estimated based on other companies in the industry. The simplified method is utilized in determining the expected term.

Based on the assumptions noted above, the weighted average estimated fair values of the options granted during the three months ended September 30, 2008 and 2007 were \$4.76 and \$5.05, respectively and \$4.96 and \$5.20 during the nine months ended September 30, 2008 and 2007, respectively.

**Non-Employee Stock Compensation**

The Company has issued nonstatutory common stock options to consultants to purchase shares of common stock. Such options vest over a service period ranging from immediately to four years. After January 1, 2006, all stock options were issued with a four year vesting period.

The fair value at the date of grant, which is subject to adjustment at each vesting date based upon the fair value of the Company's common stock, was determined using the Black-Scholes model with the following assumptions:

	Nine Months Ended September 30,	
	2008	2007
Risk free interest rate	3%	4.73%
Expected life of option (years)	10.0	6.0
Expected volatility of stock	43.00%	45.00%

## Edgar Filing: AtriCure, Inc. - Form 10-Q

Weighted-average volatility	43.00%	45.00%
Dividend yield	0.00%	0.00%

The values attributable to non-employee options have been amortized over the service period on a graded vesting method and the vested portion of these options was re-measured at each vesting date. No non-employee options were granted during the three months ended September 30, 2008 or September 30, 2007.

Stock compensation expense (income) with respect to non-employee stock options totaled \$6,999 and \$36,863 for the three month period ended September 30, 2008 and 2007, respectively and \$27,517 and \$377,594 for the nine months ended September 30, 2008 and 2007, respectively.

**Table of Contents**

Certain of the Company's share-based payment arrangements are outside the scope of SFAS No. 123(R) and are subject to Emerging Issues Task Force (EITF) Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, which requires vested stock options held by certain non-employee consultants to be accounted for as liability awards until these awards are exercised or forfeited. The fair value of these awards is remeasured at each financial statement date until the awards are settled or expire. During the three and nine months ended September 30, 2008, \$48,624 and \$215,055, respectively, of benefit was recorded as a result of the remeasurement of the fair value of these awards. As of September 30, 2008, vested options to acquire 54,660 shares of common stock held by non-employee consultants remained unexercised and a liability of \$348,307 was included in accrued liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability as of September 30, 2007 was not material.

**Employee Stock Purchase Plan (ESPP)**

Effective with the first offering period beginning July 1, 2008, the Company has established its 2008 Employee Stock Purchase Plan (ESPP), whereby the Company has initially made available 300,000 shares for future issuance to employee participants in the ESPP. Beginning on January 1, 2009 and on the first day of each fiscal year thereafter during the term of the ESPP, the number of shares available for sale under the ESPP shall be increased by the lesser of (i) two percent (2%) of the Company's outstanding shares of Common Stock as of the close of business on the last business day of the prior calendar year, not to exceed 600,000 shares, or (ii) a lesser amount determined by the Board. Under the terms of the Plan, there are two six-month offering periods per year, and employees can choose to have up to 10% of their salary withheld to purchase common stock of the Company. Stock will be purchased at 85% of the market price of the Company's common stock at the beginning or at the end of the offering period, whichever is less. Stock compensation expense with respect to the ESPP totaled \$60,858 for the three month period ended September 30, 2008.

**12. SEGMENT AND GEOGRAPHIC INFORMATION**

The Company considers reporting segments in accordance with SFAS 131, Disclosure about Segments of an Enterprise and Related Information. The Company develops, manufactures, and sells medical devices designed to create precise lesions, or scars, in cardiac tissue. These devices are developed and marketed to a broad base of medical centers in the United States and internationally. Management considers all such sales to be part of a single operating segment.

Geographic revenues were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
United States	\$ 12,437,596	\$ 10,221,870	\$ 36,899,634	\$ 30,578,798
International	2,364,405	1,832,589	6,291,026	4,578,650
Total	\$ 14,802,001	\$ 12,054,459	\$ 43,190,660	\$ 35,157,448

Substantially all of the Company's long-lived assets are located in the United States.



---

## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Form 10-Q and our audited financial statements and notes thereto as of and for the year ended December 31, 2007 included in our Form 10-K, as amended, for the year ended December 31, 2007 filed with the Securities and Exchange Commission to provide an understanding of our results of operations, financial condition and cash flows.

### **Forward-Looking Statements**

This Form 10-Q, including the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" contains forward-looking statements regarding our future performance. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors, including those set forth under "Risk Factors" in our annual report on Form 10-K, as amended, for the year ended December 31, 2007. Forward-looking statements convey our current expectations or forecasts of future events. All statements contained in this Form 10-Q other than statements of historical fact are forward-looking statements. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words "may," "continue," "estimate," "intend," "plan," "will," "believe," "project," "expect," "anticipate" and similar expressions may identify forward-looking statements, but the use of these words does not necessarily mean that a statement is not forward-looking. With respect to the forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

These forward-looking statements speak only as of the date of this Form 10-Q. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

### **Overview**

We are a medical device company and a leader in developing, manufacturing and selling innovative cardiac ablation products designed to create precise lesions, or scars, in cardiac, or heart, tissue. Our primary product line, which accounts for a majority of our revenues, is our AtriCure Isolator® bipolar ablation system. Our Isolator® system consists primarily of a compact power generator known as an ablation and sensing unit, or ASU, a switchbox unit, or ASB, which allows physicians to toggle between multiple products and multiple configurations of our Isolator® clamps, including our recently introduced Isolator Synergy® clamps. We sell two configurations of our clamps, one designed for ablation during open-heart, or open, procedures and one designed for ablation during sole-therapy minimally invasive procedures. We also sell a multifunctional bipolar Pen which is often used by physicians in combination with our Isolator® system to ablate cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. Additionally, we sell various configurations of enabling devices, such as our Lumitip® dissection tool. During the first quarter of 2008, we introduced our ORlab® mapping system and our Coolrail® linear ablation device which is cleared by the FDA for the ablation of cardiac tissue. The Coolrail® device is being adopted by physicians to perform an expanded lesion set primarily during minimally invasive procedures. In August of 2007, we acquired a cardiac cryoablation product line, which uses extreme cold to ablate tissue. Prior to our acquisition of the product line, we sold the product line as a distributor.

We commenced a full commercial release of our primary product line, the Isolator® system for use during open heart procedures in 2003, and have brought new products to market over time. During 2005, we commercialized the Isolator® system for use during minimally invasive sole-therapy procedures. In August 2005, we raised net proceeds of \$43.2 million through an initial public offering. Since then, we have invested heavily in expanding our product development organizations and activities and building our sales and marketing organizations and activities.

Medical journals have described the adoption by leading cardiac surgeons of our Isolator® bipolar ablation clamp system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiac surgeons, treatment guidelines as published by the Heart Rhythm Society and publications in medical journals have described our Isolator® system as a standard treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures designed to treat patients with AF.

In the United States, we primarily sell our products through our direct sales force. AtriCure Europe B.V., our wholly-owned European subsidiary incorporated and based in the Netherlands, sells our products throughout Europe, primarily through distributors,

**Table of Contents**

with the exception of Germany, Switzerland and Austria, we sell directly through our sales force. Additionally, we sell our products to other international distributors, primarily in Asia, South America and Canada. Our business is primarily transacted in U.S. dollars, with the exception of transactions with our European subsidiary, which are primarily transacted in Euros. Our sales outside of the United States represented 16.0% of our revenues for the three months ended September 30, 2008, and 14.6% of our revenues for the nine months ended September 30, 2008.

In the United States, substantially all of our products have been cleared by the FDA for the ablation, or destruction, of cardiac tissue and none have been cleared for the treatment of AF. Additionally, our multifunctional Pen has been cleared by the FDA for cardiac tissue ablation and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. We may only promote our products to doctors and provide education and training on the use of our devices for their cleared indications, which does not include the treatment of AF. While the FDA does not prevent doctors from using products off-label, we cannot market a product for an off-label use.

We are in the process of conducting a clinical trial, known as ABLATE, to evaluate the safety and effectiveness of our Isolator<sup>®</sup> system for the treatment of patients who have permanent AF and are undergoing a concomitant open-heart procedure. If this trial is successful, we intend to seek FDA approval as early as 2010 for the use of our Isolator<sup>®</sup> system during open procedures to treat patients with permanent AF. Through October 26, 2008, 30 patients have been treated as part of this trial. During the third quarter of 2008, the FDA fully approved an investigational device exemption ( IDE ) for a second arm to the ABLATE pivotal clinical trial to evaluate the safety and effectiveness of our Isolator<sup>®</sup> system for the treatment of patients who have persistent AF and are undergoing a concomitant open-heart procedure.

We have filed a 510(k) notification with the FDA and during the second quarter of 2008, an IDE was conditionally approved by the FDA to conduct a clinical trial to evaluate the safety and effectiveness of our left atrial appendage exclusion system to occlude the left atrial appendage. Enrollment in the trial began in October of 2008. We believe the market for our left atrial appendage exclusion system is large and represents a significant new growth opportunity for us. Our left atrial appendage exclusion system is currently being utilized and has been safely and effectively implanted in humans as part of a clinical evaluation in Europe.

We plan to release our new disposable, cryoablation probe during the first half of 2009 and believe it will be adopted by physicians, in combination with our other products, to create ablations during certain open-heart procedures.

Our costs and expenses consist of cost of revenues, research and development expenses and selling, general and administrative expenses. Cost of revenues consists principally of the cost of purchasing materials and manufacturing our products. Research and development expenses consist principally of expenses incurred with respect to internal and external research and development activities and the conduct of clinical activities and trials. Selling, general and administrative expenses consist principally of costs associated with our sales, marketing and administrative functions, and unrestricted educational grants to medical institutions.

**Table of Contents****Results of Operations****Three months ended September 30, 2008 compared to September 30, 2007**

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenues:

	Three Months Ended September 30, 2008		Three Months Ended September 30, 2007	
	Amount	% of Revenue	Amount	% of Revenue
Revenues	\$ 14,802	100.0%	\$ 12,054	100.0%
Cost of revenues	3,396	22.9%	2,760	22.9%
Gross profit	11,406	77.1%	9,294	77.1%
Operating expenses:				
Research and development expenses	3,009	20.3%	2,398	19.9%
Selling, general and administrative expenses	10,215	69.0%	9,805	81.3%
Total operating expenses	13,224	89.3%	12,203	101.2%
Loss from operations	(1,818)	-12.3%	(2,909)	-24.1%
Other income (expense):				
Interest expense	(174)	-1.2%	(49)	-0.4%
Interest income	80	0.5%	286	2.4%
Other	142	1.0%	74	0.6%
Net loss	\$ (1,770)	-12.0%	\$ (2,598)	-21.6%

**Revenues.** Total revenues increased \$2.7 million, or 22.8%, from \$12.1 million for the three months ended September 30, 2007 to \$14.8 million for the three months ended September 30, 2008. The increase in revenues was due primarily to an increase in unit sales of existing products and the sale of new products. Fluctuations in currency exchange rates had an insignificant impact on total revenues.

**Cost of revenues.** Cost of revenues increased \$0.6 million, from \$2.8 million for the three months ended September 30, 2007 to \$3.4 million for the three months ended September 30, 2008, due primarily due to an increase in units sold. Cost of revenues as a percentage of revenues for the periods was consistent at 22.9%.

**Research and development expenses.** Research and development expenses increased \$0.6 million, from \$2.4 million for the three months ended September 30, 2007 to \$3.0 million for the three months ended September 30, 2008. As a percentage of revenues, research and development expenses increased from 19.9% for the three months ended September 30, 2007 to 20.3% for the three months ended September 30, 2008. The increase was primarily attributable to increased laboratory and consulting activities in support of product development activities and increased clinical trial expenses, primarily related to our ABLATE clinical trial.

**Selling, general and administrative expenses.** Selling, general and administrative expenses increased \$0.4 million, from \$9.8 million for the three months ended September 30, 2007 to \$10.2 million for the three months ended September 30, 2008. The increase was primarily attributable to increase sales compensation expense. As a percentage of total revenues, selling, general and administrative expenses decreased from 81.3% for the three months ended September 30, 2007 to 69.0% for the three months ended September 30, 2008.

**Net interest income (expense).** Net interest expense was \$0.1 million for the three months ended September 30, 2008 compared to net interest income of \$0.2 million for the three months ended September 30, 2007. The decrease in net interest income was primarily due to borrowings under our credit facility and the write-off of fees related to our previous credit facility and a reduction in our net cash position and the effective rate on cash and investments.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

**Other income.** Other income consists of grant income, foreign currency transaction gain and non-employee option expense related to the fair market value change for fully vested options outstanding for consultants, which are accounted for as free standing derivatives.

Grant income was \$0.1 million for the three months ended September 30, 2008 as compared to \$0.1 million for the three months ended September 30, 2007. Grant income consisted of income related to expense sharing under a grant for research and development related activities. The remaining increase for the three months ended September 30, 2008 was due to foreign currency gains and the change in the fair value of the liability related to fully-vested non-employee options outstanding.

**Table of Contents****Nine months ended September 30, 2008 compared to September 30, 2007**

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenues:

	Nine Months Ended September 30,			
	2008		2007	
	(dollars in thousands)			
	Amount	% of Revenue	Amount	% of Revenue
Revenues	\$ 43,191	100.0%	\$ 35,157	100.0%
Cost of revenues	10,122	23.4%	7,518	21.4%
Gross profit	33,069	76.6%	27,639	78.6%
Operating expenses:				
Research and development expenses	8,035	18.6%	8,455	24.0%
Selling, general and administrative expenses	32,573	75.4%	30,125	85.7%
Total operating expenses	40,609	94.0%	38,580	109.7%
Loss from operations	(7,540)	-17.5%	(10,941)	-31.1%
Other income (expense):				
Interest expense	(256)	-0.6%	(142)	-0.4%
Interest income	314	0.7%	705	2.0%
Other	514	1.2%	691	2.0%
Net loss	(6,968)	-16.1%	(9,688)	-27.6%

**Revenues.** Total revenues increased \$8.0 million, or 22.9%, from \$35.2 million for the nine months ended September 30, 2007 to \$43.2 million for the nine months ended September 30, 2008. The increase in revenues was due primarily to an increase in unit sales of existing products and the sale of new products. Fluctuations in currency exchange rates resulted in an insignificant increase to revenues.

**Cost of revenues.** Cost of revenues increased \$2.6 million, from \$7.5 million for the nine months ended September 30, 2007 to \$10.1 million for the nine months ended September 30, 2008. The increase was primarily due to an increase in units sold and a change in product mix. As a percentage of revenues, cost of revenues increased from 21.4% for the nine months ended September 30, 2007 to 23.4% for the nine months ended September 30, 2008. The increase in cost of revenues as a percentage of revenues was primarily due to the introduction and sale of the ORlab system, which carries a higher cost of revenues than our disposable products and an increased mix of international sales, which have a lower average selling price than sales in the United States.

**Research and development expenses.** Research and development expenses decreased \$0.4 million, from \$8.5 million for the nine months ended September 30, 2007 to \$8.0 million for the nine months ended September 30, 2008. As a percentage of revenues, research and development expenses decreased from 24.0% for the nine months ended September 30, 2007 to 18.6% for the nine months ended September 30, 2008. The decrease was primarily attributable to the redeployment during the second quarter of 2007 of several individuals who previously focused on clinical activities to selling activities, which are recorded as a component of selling, general and administrative expenses, partially offset by increased expenditures in support of new product development and clinical trials.

**Selling, general and administrative expenses.** Selling, general and administrative expenses increased \$2.4 million, from \$30.1 million for the nine months ended September 30, 2007 to \$32.6 million for the nine months ended September 30, 2008. The increase was primarily attributable to an increase in sales compensation, partially offset by reductions in overall administrative expenses. As a percentage of total revenues, selling, general and administrative expenses decreased from 85.7% for the nine months ended September 30, 2007 to 75.4% for the nine months ended September 30, 2008.

## Edgar Filing: AtriCure, Inc. - Form 10-Q

**Net interest income.** Net interest income was \$0.1 million for the nine months ended September 30, 2008, compared to \$0.6 million for the nine months ended September 30, 2007. The decrease was due primarily to borrowings on our credit facility, a decrease in average net cash, cash equivalents and investments outstanding and a reduced average effective interest rate.

**Other income.** Other income consists of grant income, foreign currency transaction gain and non-employee option expense related to the fair market value change for fully vested options outstanding for consultants, which are accounted for as free standing derivatives.

Grant income was \$0.2 million for the nine months ended September 30, 2008 as compared to \$0.5 million for the nine months ended September 30, 2007. Grant income consisted of income related to expense sharing under a grant for research and development related activities.

---

**Table of Contents**

Gains from foreign currency transactions were \$0.1 million for the nine months ended September 30, 2008 as compared to \$0.2 million for the nine months ended September 30, 2007. These gains are the result of partial settlements of our intercompany receivable balance with our subsidiary.

**Liquidity and Capital Resources**

As of September 30, 2008, we had cash, cash equivalents, and restricted cash of \$18.3 million and short-term and long-term debt of \$6.1 million, resulting in a net cash position of \$12.2 million. We had working capital of \$19.5 million and an accumulated deficit of \$74.3 million.

**Cash flows used in operating activities.** Net cash used in operating activities was \$4.9 million for the nine months ended September 30, 2008 and \$7.8 million for the nine months ended September 30, 2007. Net cash used in operating activities for the nine months ended September 30, 2008 was primarily attributable to the net loss of \$7.0 million, an increase in accounts receivable and inventory of \$1.6 million and \$0.2 million, respectively, and a net increase in accounts payable and accrued liabilities of approximately \$0.1 million. Net cash used by operations was partially offset by adjustments for depreciation and amortization of \$2.2 million and non-cash charges related to share-based compensation of \$1.8 million. The increase in accounts receivable was primarily due to an increase in and the timing of revenues. The increase in inventories was primarily related to anticipated growth and new product introductions. Net cash used in operating activities for the nine months ended September 30, 2007 was primarily attributable to a net loss of \$9.7 million, increases in accounts receivable and inventory of \$0.8 million and \$0.3 million, respectively, primarily due to an increase in revenues, and a net decrease in accounts payable and accrued liabilities of \$0.2 million. Net cash used by operations was partially offset by adjustments for depreciation and amortization of \$1.7 million, as well as non-cash charges related to share-based compensation of \$1.4 million, and a net decrease in other non-current assets.

**Cash flows used in investing activities.** Net cash used in investing activities was \$1.0 million for the nine months ended September 30, 2008 and \$5.0 million for the nine months ended September 30, 2007. For each of these periods, net cash used in investing activities reflected purchases of property and equipment of \$1.6 million and \$2.3 million, respectively, offset by the net purchases and maturities of investments of \$7.0 million and \$0.6 million, respectively. For the nine months ended September 30, 2008 net cash used in investing activities included the repayment of a \$0.4 million note associated with our acquisition of a product line and a shift of cash to restricted cash of \$6.0 million, and for the nine months ended September 30, 2007, net cash used in investing activities included the purchase of a product line in the amount of \$3.3 million. During the nine months ended September 30, 2008 our expenditures for property and equipment primarily consisted of \$1.0 million for the purchase of generators and other capital equipment (such as our ASB) that are loaned at no cost to medical providers who use the Company's disposable products, \$0.4 million for the purchase of computer equipment, and \$0.2 million for furniture, machinery equipment and molds.

**Cash flows provided by financing activities.** Net cash provided by financing activities was \$5.2 million for the nine months ended September 30, 2008. For the nine months ended September 30, 2008, cash flows provided by financing activities included borrowings against our credit facility in the amount of \$6.0 million, as well as proceeds from exercises of stock options of \$0.2 million. Cash provided by financing activities was partially offset by payments made on our debt and capital lease obligations and fees of \$0.9 million. During the third quarter of 2008, we entered into a new credit facility and as a result of macro economic considerations within the banking industry, we drew on the credit facility to insure access to cash should we require it. For the nine months ended September 30, 2007, cash flows provided by financing activities reflected net proceeds of \$15.3 million from the May 2007 closing of our private placement of shares of our common shares and proceeds from exercises of stock options of \$0.2 million, which were partially offset by payments made on our debt and capital lease obligations of \$0.3 million.

**Debt.** On July 1, 2008, we entered into a two-year, \$10,000,000 credit facility with National City Bank as described in Note 12 to our Condensed Consolidated Financial Statements. As a September 30, 2008, \$6.0 million was outstanding under the facility. The effective borrowing rate for the three months ended September 30, 2008 was 4.9%.

We entered into a \$5.0 million credit facility on March 8, 2005 with Lighthouse Capital Partners V, L.P. for working capital requirements and as of June 30, 2008, we had \$0.5 million in borrowings outstanding under this facility. In conjunction with entering into our new credit facility, on July 3, 2008, this credit facility was repaid in full.

## **Table of Contents**

**Uses of liquidity and capital resources.** Our future capital requirements depend on a number of factors, including possible acquisitions and joint ventures, the rate of market acceptance of our current and future products, the resources we devote to developing and supporting our products, future expenses to expand and support our sales and marketing efforts, costs relating to changes in regulatory policies or laws that affect our operations and costs of filing, prosecuting, defending and enforcing our intellectual property rights. We expect to increase capital expenditures consistently with our anticipated growth in research and development, manufacturing, infrastructure and personnel.

We believe that our current cash and cash equivalents, combined with our availability under our credit facility, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next 12 months. If these sources of cash are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or seek additional borrowings. The sale of additional equity or convertible debt securities could result in dilution to our stockholders. If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with our common stock and could contain covenants that would restrict our operations. Additional financing may not be available at all, or in amounts or terms acceptable to us. If we are unable to obtain this additional financing, we may be required to reduce the scope of our planned research and development and selling and marketing efforts.

## **Contractual Obligations and Commitments**

### **Off-Balance-Sheet Arrangements**

As of September 30, 2008, we had operating lease agreements not recorded on the Condensed Consolidated Balance Sheet. Operating leases are utilized in the normal course of business.

### **Inflation**

Inflation has not had a significant impact on our historical operations and we do not expect it to have a significant impact on our results of operations or financial condition in the foreseeable future.

### **Seasonality**

During the third quarter, we typically experience a sequential decline in revenues as compared to second quarter revenues. We attribute this primarily to the elective nature of the procedures in which our products are typically used, which we believe arises from fewer people choosing to undergo elective procedures during the summer months.

## **Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Accordingly, this discussion should be read in conjunction with our Condensed Consolidated Financial Statements and related Notes. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and disclosures of contingent assets and liabilities at the date of the financial statements. On a periodic basis, we evaluate our estimates, including those related to sales returns and allowances, accounts receivable, inventories and share-based compensation. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates under different assumptions or conditions. Our Annual Report on Form 10-K for the fiscal year ending December 31, 2007 includes additional information about the Company, our operations, our financial position, our critical accounting policies and accounting estimates, and should be read in conjunction with this Quarterly Report.

## **Recent Accounting Pronouncements**

Please see Note 2 in the Notes to the Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.



**Table of Contents****Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We have financial instruments accounted for as free-standing derivatives related to certain of the Company's share-based payment arrangements that are outside the scope of SFAS No. 123(R) and are subject to Emerging Issues Task Force (EITF) Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, which requires vested stock options held by certain non-employee consultants to be accounted for as liabilities until these awards are exercised or forfeited. The fair value of these awards is remeasured at each financial statement date until the awards are settled or expire. During the three months ended September 30, 2008, \$48,624 of benefit was recorded based on the remeasurement of these options. During the nine months ended September 30, 2008, \$215,055 of benefit was recorded based on the remeasurement of these options. As of September 30, 2008, stock options to acquire 54,660 shares of common stock held by non-employee consultants remained unexercised and a liability of \$348,307 at September 30, 2008 is included in accrued liabilities in the accompanying condensed consolidated balance sheet. We are exposed to the volatility of the market price of our stock.

We are exposed to various market risks, which include potential losses arising from adverse changes in market rates and prices, such as foreign exchange fluctuations and changes in interest rates. For the nine months ended September 30, 2008 and 2007, products sold by AtriCure Europe B.V. accounted for 7.7% and 6.4%, respectively, of our total revenues. Since such revenues were primarily denominated in Euros, we have exposure to exchange rate fluctuations between the Euro and the U.S. Dollar. We recognized a benefit of approximately 1% in our consolidated revenues for the nine months ended September 30, 2008 from currency exchange rate fluctuation. To date, the effect of the foreign exchange rate fluctuations on our financial results has not been significant. In the nine months ended September 30, 2008, we recorded foreign currency transaction gains of \$76,884 in connection with partial settlements of our intercompany receivable balance with our subsidiary. For revenues denominated in Euros, if there is an increase in the rate at which Euros are exchanged for U.S. Dollars, it will require more Euros to equal a specified amount of U.S. Dollars than before the rate increase. In such cases, and if we price our products in Euros, we will receive less in U.S. Dollars than we did before the rate increase went into effect. The impact of an aggregate decline of 10% in foreign currency exchange rates relative to the U.S. dollar on our results of operations and financial position would not be significant. If we price our products in U.S. Dollars and competitors price their products in Euros, an increase in the relative strength of the U.S. Dollar could result in our price not being competitive in a market where business is transacted in Euros. The Euro to U.S. dollar conversion rate fluctuations may impact our reported revenues and expenses.

We believe our cash and cash equivalents are invested in a conservative manner, with cash preservation being our primary investment objective, the value of the securities we hold will fluctuate with changes in the financial markets including, among other things, changes in interest rates, credit quality and general volatility. We manage this risk by investing in high quality investment grade securities with very short-term maturities.

We are subject to market risk from exposure to changes in the interest rate on borrowings under our credit facility. We had no fixed rate long-term debt at September 30, 2008. An increase of 1% in our variable rate on our outstanding debt would not have a material effect on our financial condition, results of operations, or liquidity.

**Item 4. Controls and Procedures  
Disclosure Controls and Procedures**

We have evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Securities Exchange Act of 1934 (the Exchange Act), as of the end of the period covered by this report. Our management, including the Chief Executive Officer and Chief Financial Officer, supervised and participated in the evaluation. Based on the evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's forms and rules. Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that control objectives are met. Because of inherent limitations in all control systems, no evaluation of controls can provide assurance that all control issues and instances of fraud, if any, within a company will be detected. Additionally, controls can be circumvented by individuals, by collusion of two or more people, or by management override. Over time, controls can become inadequate because of changes in conditions or the degree of compliance may deteriorate. Further, the design of any system of controls is based in part upon assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Because of the inherent limitations in any cost-effective control system, misstatements due to errors or fraud may occur and not be detected.

---

**Table of Contents**

**Changes in Internal Control Over Financial Reporting**

There has been no change in our internal control over financial reporting that occurred during the three or nine months ended September 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are not party to any material pending or threatened litigation, except as described below:

*Class Action Lawsuit*

We and certain of our current and former officers were named as defendants in a purported securities class action lawsuit filed in the United States District Court for the Southern District of New York (Levine v. AtriCure, Inc., Case No. 06 CV 14324 (United States District Court for the Southern District of New York)). The suit alleges violations of the federal securities laws and seeks damages on behalf of purchasers of our common stock during the period from our Initial Public Offering in August 2005 through February 16, 2006. We believe that the allegations are without merit and intend to vigorously defend against them. Our motion to dismiss the lawsuit for lack of subject matter jurisdiction was denied in September 2007 and a motion for reconsideration of that denial is pending.

*Department of Justice Investigation*

The Company received a letter on October 27, 2008 from the U.S. Department of Justice-Civil Division (the DOJ) informing the Company that the DOJ was conducting an investigation for potential False Claims Act and common law violations relating to the Company's surgical ablation devices. Specifically, the letter states that the DOJ is investigating the Company's marketing practices utilized in connection with its surgical ablation system to treat atrial fibrillation, a specific use outside the Federal Food and Drug Administration's 510(k) clearance. The letter also states that the DOJ is investigating whether AtriCure instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes. On November 3, 2008, the Company received a letter from the DOJ outlining a document request. The Company is in the process of reviewing and compiling the requested information.

We may from time to time become a party to additional legal proceedings.

**Item 1A. Risk Factors**

The risk factors set forth below should be read in conjunction with the Risk Factors section in our Annual Report on Form

10-K, as amended. The risk factors described in our Annual Report on Form 10-K, as amended, and set forth below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition and/or operating results.

**The current volatility in global economic conditions and the financial markets may adversely affect our business and results of operations.**

The current volatility and disruption to the capital and credit markets has reached unprecedented levels and has significantly adversely impacted global economic conditions, resulting in additional significant recessionary pressures and further declines in consumer confidence and economic growth. These conditions have led and could further lead to reduced consumer spending. Because some of our products, particularly those used in minimally invasive procedures, are often used in elective procedures, we believe that the macroeconomic environment and the deteriorating consumer confidence and spending have impacted and could continue to impact current procedure volume trends. A continuing impact on procedure volumes could materially adversely affect our business and results of operations.

**Table of Contents**

**The Department of Justice is investigating aspects of our operations, and the process of the investigation and/or the results of the investigation may have an adverse impact on our business, results of operations, financial condition and liquidity.**

As discussed above in Part II, Item 1 – Legal Proceedings, we have been notified that the U.S. Department of Justice-Civil Division (the DOJ) is conducting an investigation for potential False Claims Act and common law violations relating to our surgical ablation devices. Specifically, the DOJ is investigating our marketing practices utilized in connection with our surgical ablation system to treat atrial fibrillation, a specific use outside the Federal Food and Drug Administration’s 510(k) clearance. The letter also states that the DOJ is investigating whether we instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes. We are fully cooperating with the DOJ investigation. At this point, we are unable to predict the duration, scope or result of the DOJ investigations or whether the DOJ will commence any legal action. We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting the use of our products for non-FDA-approved, or off-label, uses, or if we are found to have caused the submission of improper claims to Medicare or other government healthcare programs, which could have an adverse impact on our business, results of operations, financial condition and liquidity. In addition, the DOJ investigation could lead to negative publicity, will require that we spend time and resources, and may impact the continued use of our products by existing customers and our ability to continue to develop markets for our products which, in any case, could have an adverse impact on our business, results of operations, financial condition and liquidity.

**Table of Contents**

**Item 6. Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Rule 13a-14(a) Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Rule 13a-14(a) Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Executive Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Financial Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AtriCure, Inc.

(REGISTRANT)

Date: November 7, 2008

/s/ David J. Drachman  
David J. Drachman  
President and Chief Executive Officer

(Principal Executive Officer)

Date: November 7, 2008

/s/ Julie A. Piton  
Julie A. Piton  
Vice President, Finance and Administration and Chief Financial  
Officer

(Principal Financial and Accounting Officer)

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Rule 13a-14(a) Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Rule 13a-14(a) Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Executive Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification pursuant to 18 U.S.C. Section 1350 by the Chief Financial Officer, as adopted, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002